Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.
Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd N, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB.
Weathers SP, et al.
Clin Cancer Res. 2020 Jul 15;26(14):3565-3577. doi: 10.1158/1078-0432.CCR-20-0176. Epub 2020 Apr 16.
Clin Cancer Res. 2020.
PMID: 32299815
Free PMC article.
Clinical Trial.